secwatch.observer — SEC 8-K summary
======================================

Issuer:     WEST PHARMACEUTICAL SERVICES INC (WST)
CIK:        0000105770
Form:       8-K
Filed at:   2025-07-24T23:59:59+00:00
Accession:  0000105770-25-000062
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

West Pharma beats Q2, raises FY 2025 guidance; declares Q4 dividend
-------------------------------------------------------------------

- Net sales $766.5M (+9.2% YoY); diluted EPS $1.82 vs $1.51; adjusted EPS $1.84 vs $1.52.
- FY 2025 net sales guidance raised to $3.04-3.06B (from $2.945-2.975B); adjusted EPS raised to $6.65-6.85.
- Proprietary Products sales $619.8M (+10.7%); HVP components up 11.3% driven by GLP-1 elastomer growth.
- Board declares Q4 dividend $0.22/share, payable Nov 19, record Nov 12.
- First-half 2025 free cash flow $160M (from $92.4M); repurchased 552,593 shares for $134M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/105770/000010577025000062/0000105770-25-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/105770/000010577025000062/wst-20250724.htm
  HTML page:      https://secwatch.observer/filing/0000105770-25-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer